MaxCyte | DEF 14A: Definitive information statements
Apr 27 05:22
MaxCyte | 8-K: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
Mar 13 04:15
MaxCyte | 8-K: Current report
Mar 6 05:21
MaxCyte | 8-K: Current report
Jan 27 05:50
MaxCyte | 8-K: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
Jan 8 13:00
MaxCyte | 8-K: Current report
Dec 12, 2023 05:30
MaxCyte | 8-K: MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
Nov 9, 2023 05:12
MaxCyte | 8-K: Current report
Oct 5, 2023 04:14
MaxCyte | 8-K: MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
Aug 10, 2023 04:16
MaxCyte | 8-K: Current report
Jun 23, 2023 21:27
MaxCyte | 8-K: MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 11, 2023 04:14
MaxCyte | DEF 14A: Definitive proxy statements
Apr 29, 2023 04:22
MaxCyte | 8-K: Current report
Mar 28, 2023 21:40
MaxCyte | 8-K: Current report
Mar 16, 2023 04:15
MaxCyte | 8-K: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
Mar 7, 2023 06:04
MaxCyte | 8-K: Current report
Dec 1, 2022 21:30
MaxCyte | 8-K: MaxCyte Reports Third Quarter 2022 Financial Results 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance
Nov 10, 2022 05:15
MaxCyte | 8-K: MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30%
Aug 11, 2022 04:15
MaxCyte | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Jul 15, 2022 04:37
MaxCyte | 8-K: Current report
Jul 1, 2022 04:44
No Data
No Data